Zacks Investment Research upgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a sell rating to a hold rating in a research note published on Thursday morning.

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

Other equities research analysts have also issued research reports about the company. BidaskClub lowered HUTCHISON CHINA/S from a buy rating to a hold rating in a research report on Thursday, August 23rd. MED assumed coverage on HUTCHISON CHINA/S in a research report on Monday, July 23rd. They set a positive rating on the stock.

Shares of HCM opened at $30.16 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.67 and a quick ratio of 4.55. The stock has a market capitalization of $4.01 billion, a PE ratio of -137.09 and a beta of 0.01. HUTCHISON CHINA/S has a 1 year low of $25.76 and a 1 year high of $42.25.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in HUTCHISON CHINA/S by 375.0% during the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock worth $1,040,000 after buying an additional 25,500 shares during the period. Allianz Asset Management GmbH increased its position in HUTCHISON CHINA/S by 47.3% during the third quarter. Allianz Asset Management GmbH now owns 447,494 shares of the company’s stock worth $14,405,000 after buying an additional 143,765 shares during the period. Bellevue Group AG increased its position in HUTCHISON CHINA/S by 20.3% during the third quarter. Bellevue Group AG now owns 400,029 shares of the company’s stock worth $12,877,000 after buying an additional 67,493 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in HUTCHISON CHINA/S by 9.9% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 133,479 shares of the company’s stock worth $4,297,000 after buying an additional 12,049 shares during the period. Finally, Alps Advisors Inc. increased its position in HUTCHISON CHINA/S by 22.5% during the third quarter. Alps Advisors Inc. now owns 235,130 shares of the company’s stock worth $7,569,000 after buying an additional 43,197 shares during the period. 11.45% of the stock is currently owned by institutional investors.

HUTCHISON CHINA/S Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

See Also: How to Invest in an Index Fund

Get a free copy of the Zacks research report on HUTCHISON CHINA/S (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.